U
LAB icon

UBS’s Standard BioTools LAB Stock Holding History

UBS’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$64K Buy
+2,600
New +$73.1K ﹤0.01% 6528
2014
Q1 		– Sell
-21,500
Closed -$823K – 10608
2013
Q4 		$823K Buy
+21,500
New +$633K ﹤0.01% 3758

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS's LAB Position: Q3 2014 in Review

UBS reduced its Standard BioTools (LAB) stake by 71% in Q3 2014, selling an estimated $110K and leaving 1,600 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #7133.

UBS first reported a position in LAB in Q2 2013 and has held it in 6 quarters since. The position peaked at $1.43M in Q4 2013. 99 funds tracked by Wall St. Rank hold LAB as of Q3 2014.

  • UBS held 1,600 shares of Standard BioTools worth $39K as of Q3 2014.
  • UBS sold 3,915 Standard BioTools shares in Q3 2014, an estimated $110K.
  • Standard BioTools made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7133 holding.
  • UBS first reported a position in Standard BioTools in Q2 2013 and has held it in 6 quarters since.
  • UBS's Standard BioTools position peaked at $1.43M in Q4 2013.
  • 99 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.